Evaluation of the Marker of Hypercoagulability Prothrombin Fragment F 1+2 in Patients with Mechanical or Biological Heart Valve Prostheses

Claudia Natália Ferreira, Lauro Mello Vieira, Luci Maria Sant'Ana Dusse, Carlos Faria Santos Amaral, William Antônio de Magalhães Esteves, Lúcia Maria Amorim Fenelon, Maria das Graças Carvalho

Belo Horizonte, MG - Brazil

Objective - To investigate whether patients with heart valve prostheses and similar International Normalized Ratios (INR) have the same level of protection against thromboembolic events, that is, whether the anticoagulation intensity is related to the intensity of hypercoagulability suppression.

Methods - INR and plasma levels of prothrombin fragment 1+2 (F1+2) were assessed in blood samples of 27 patients (7 with mechanical heart valves and 20 with biological heart valves) and 27 blood samples from healthy donors that were not taking any medication.

Results - Increased levels of F1+2 were observed in blood samples of 5 patients with heart valve prostheses taking warfarin. These findings reinforce the idea that even though patients may have INRs, within the therapeutic spectrum, they are not free from new thromboembolic events.

Conclusion - Determination of the hypercoagulability marker F1+2 might result in greater efficacy and safety for the use of oral anticoagulants, resulting in improved quality of life for patients.

Keywords: heart valve prostheses, warfarin, prothrombin fragment 1+2

Oral anticoagulants have been widely used to decrease the levels of vitamin K- dependent factors, that is II, VII, IX, and X, contributing to decreased thrombotic risk. Paradoxically, the use of anticoagulants reduces plasma levels of natural anticoagulants, C and S proteins, thus facilitating hypercoagulability. This fact raises concerns about the effects of oral anticoagulant use and its effects on hemostatic balance, protecting or not protecting the patient. Monitoring of oral anticoagulant therapy through measuring prothrombin time (PT) has contributed to substantial advances, revealed by the expression of the results of this test in terms of the International Normalized Ratio (INR), which contributes to the reduction of differences between results, therefore, making them more reliable. However, the use of prothrombin time as the method of choice for monitoring patients with heart valves who are taking oral anticoagulants is controversial. Are patients protected when the therapeutic range of INR is similar to that expected? The number of patients with heart valve prostheses is significant, and they need anticoagulation medication for the rest of their lives, with constant monitoring. The main remaining problem is the thromboembolic potential of these valves. Although the use of INR represents an advance in the interpretation of prothrombin time, some difficulties in monitoring anticoagulation therapy still occur, including limitations on the use of the INR system to assess the results of prothrombin time, floating on vitamin K intake, concomitant use of other drugs, difficulty in comprehension and/or acceptance of oral anticoagulants by the patients, concurrent diseases, and a genetic predisposition to thrombosis. In addition to factors already mentioned that contributed to the instability of oral anticoagulation, common to all patients receiving oral anticoagulants, factors are also inherent in patients with heart valve prostheses, which include the type, site, and number of replaced valves.
However, no consistent information is available on the extension of hemostatic mechanism activation in patients with a history of systemic thromboembolism without a definite defect in the coagulation system\(^1\). Thus, the benefits of the use of activation markers of coagulation, such as F1+2, have been emphasized for monitoring oral anticoagulant therapy\(^2\), because reduction in plasma levels of F1+2 was demonstrated in patients with oral anticoagulant treatment. Thus, some investigators have presumed that warfarin dosage may be adjusted based on F1+2 concentrations\(^3\). Because procoagulant plays a fundamental role in the result of procoagulant stimulation, the quantification of F1+2 levels is considered one of the most important markers of hypercoagulability, reflecting the activation rate of procoagulant and, consequently, the levels of thrombin formed\(^6\). Elevation in F1+2 levels was observed in familial prethrombotic conditions, such as in antithrombin AT-III and C and S protein deficiencies.

The main purpose of this study was to investigate whether patients with similar INRs have the same protection against thromboembolic events, that is, whether the intensity of anticoagulation is related to the level of hypercoagulability suppression. This study may contribute to a better understanding of the regulation of hemostatic mechanisms in therapy with oral anticoagulants and may also contribute to a better laboratory assessment of oral anticoagulant therapy in patients with heart valve prostheses, which would be clinically useful in the follow-up and prognosis of these patients.

### Methods

We evaluated 54 patients: 27 patients were normal controls, 10 patients taking acetylsalicylic acid (Bio-AAS) had biological heart valve prostheses, 10 patients taking warfarin (Bio-War) had biological heart valve prostheses, and the remaining patients were taking warfarin (Mec-War) and had mechanical heart valve prostheses. Patients were consecutively enrolled at Hospitais das Clínicas, Vera Cruz, and Socor and were referred to the Laboratório de Hematologia Clínica da Faculdade de Farmácia da UFMG (Laboratory of Clinical Hematology of the College of Pharmacy of the Federal University of Minas Gerais). All the patients received stable doses of warfarin (n=17) and acetylsalicylic acid (n=10), for at least 1 month. The present study was approved by the Conselho Técnico Científico do Hospital das Clínicas da UFMG (Scientifical Technical Board of the Clinical Hospital of UFMG). Table 1 summarizes demographic characteristics and the number of patients from both study groups.

Venipunctures were performed in patients and in the control group after an 8-hour fast, and a 5-mL blood sample was drawn with vacuum tubes (Vacutainer system tube - Becton-Dickinson) containing 3.8% sodium citrate (anti-coagulant: blood proportion 9:1), and processed as follows: blood samples were centrifuged at 2,500 rpm for 10 minutes to obtain plasma poor in platelets. After centrifugation, plasma samples were aliquoted for different purposes: one was separated for analysis of prothrombin time and INR up to 3 hours after collection. The other was frozen at -20°C until the simultaneous testing of F1+2 from both patients and controls.

Prothrombin time and INR were determined with a coagulometer ST\(_2\)–BIO (Diagnostica Stago, Asnieres-sur-Seine, France) that used rabbit brain thromboplastin (Biolab Merieux, São Paulo, Brasil, ISI = 1.83). All plasma pools were diluted with saline solution (0.85%\(\)) to determine the standard-curve. Plasma concentrations of F1+2 were determined with the enzyme immunoassay Enzygnost F1+2 micro (Behring Diagnostics GmbH, Marburg, Germany). This ELISA assay also uses microtitration plates, and readings were conducted on Bio – Rad (model 550).

### Results

The results are presented in table II as mean ± standard deviation. Differences between the groups were tested with analysis of variance followed by Tukey’s test. A statistical significance level of 5% was adopted.

Regarding prothrombin time and INR, no significant difference was observed between the control group and the group of patients taking acetylsalicylic acid who had biological heart valves, whereas a significant statistical difference was observed between the control group and the group

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Control</th>
<th>Bio-AAS</th>
<th>Bio-War</th>
<th>Mec-War</th>
</tr>
</thead>
<tbody>
<tr>
<td>AP (%)</td>
<td>84.2</td>
<td>83.0</td>
<td>48.9</td>
<td>38.6</td>
</tr>
<tr>
<td></td>
<td>(11.4)</td>
<td>(10)</td>
<td>(15.5)</td>
<td>(8)</td>
</tr>
<tr>
<td>INR</td>
<td>1.15</td>
<td>1.19</td>
<td>2.33</td>
<td>2.83</td>
</tr>
<tr>
<td></td>
<td>(0.16)</td>
<td>(0.13)</td>
<td>(0.93)</td>
<td>(1.1)</td>
</tr>
<tr>
<td>F1+2 (µmol/L)</td>
<td>0.62</td>
<td>0.72</td>
<td>0.64</td>
<td>0.63</td>
</tr>
<tr>
<td></td>
<td>(0.22)</td>
<td>(0.36)</td>
<td>(0.41)</td>
<td>(0.48)</td>
</tr>
</tbody>
</table>

Mean and standard deviation of the results obtained from normal control, patients with biological heart valve prostheses taking acetylsalicylic acid (Bio-AAS) or warfarin (Bio-War) and with mechanical heart valve prostheses taking warfarin (Mec-War) regarding the parameters studied. PT-prothrombin time; INR- International Normalized Ratio; F1+2- prothrombin fragment F1+2.

### Table I - Characterization of the groups of individuals studied

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control</th>
<th>Bio-AAS</th>
<th>Bio-War</th>
<th>Mec-War</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients</td>
<td>27</td>
<td>10</td>
<td>10</td>
<td>7</td>
<td>54</td>
</tr>
<tr>
<td>Male sex</td>
<td>15</td>
<td>5</td>
<td>2</td>
<td>5</td>
<td>27</td>
</tr>
<tr>
<td>Female sex</td>
<td>12</td>
<td>5</td>
<td>8</td>
<td>2</td>
<td>27</td>
</tr>
<tr>
<td>Age average</td>
<td>37</td>
<td>43</td>
<td>50</td>
<td>45</td>
<td>-</td>
</tr>
<tr>
<td>(Age group)</td>
<td>(17-64)</td>
<td>(15-64)</td>
<td>(23-72)</td>
<td>(36-61)</td>
<td></td>
</tr>
</tbody>
</table>

Size of the sample (n), sex, age average, and age group of the groups studied.

**Prothrombin fragment F 1+2 in patients with heart valve prostheses**

**Ferreira et al**

**Arq Bras Cardiol**

Discussion

Through data analysis, we observed that acetylsalicylic acid did not change the results of prothrombin time or INR in patients with biological heart valves.

Patients with biological heart valves generally experience fewer thromboembolic events, compared with those with mechanical heart valves and, therefore, most of these patients use only acetylsalicylic acid. In the present study, we observed patients with plasma F1+2 levels above reference levels (tab. III). However, it is possible that other factors may be interacting in these patients, resulting in an apparent state of hypercoagulability suggested by the increased levels of F1+2.

Despite a suitable monitoring through prothrombin time, approximately 10 to 20% of the patients treated with warfarin developed thromboembolic or bleeding complications because of inadequate warfarin therapy. Although some of these complications may occur when prothrombin time is out of therapeutical range, about 50% of the complications occur when prothrombin time is within this range, strengthening the idea that the introduction of a marker hypercoagulability,
together with INR, may be very useful for improving monitoring of patients receiving oral anticoagulants.

The benefits of determining markers of activated coagulation in monitoring oral anticoagulant therapy have been studied mainly by Conway et al. 3, the first to demonstrate F1+2 suppression in patients stabilized with an oral anticoagulant. Because of that, studies have been carried out to analyze the adjustment of warfarin dosage, using as a base F1+2 concentration 4. F1+2 concentration in patients stabilized with oral anticoagulants was determined in the present study, and no correlation was observed between F1+2 concentration and the level of anticoagulation expressed as an INR. Despite the absence of a correlation between these 2 parameters, we cannot establish a parallel between the level of suppression of hypercoagulability through the results of the marker of thrombin F1+2 generator, and the intensity of anticoagulation through INR values.

Table II shows that no significant difference exists regarding F1+2 levels, between the groups using warfarin and the control groups. However, isolated cases with increased F1+2 levels were found in our study, which enabled us to make inferences about the potential for the occurrence of a new thrombotic event.

Barcellona et al 9 and Tripodi et al 4 demonstrated that F1+2 is a sensitive marker of anticoagulation, even when the intensity of treatment is very low. A statistically significant progressive decrease occurred in F1+2 levels with increasing anticoagulation up to an INR value of 3.0. The F1+2 decrease, however, was barely detectable at INR values > 3.0. The reason for this pattern is not clear.

Jafri et al 10 worked with 3 groups of patients with heart failure, and the groups were treated with placebo, low-intensity warfarin (INR = 1.2 – 1.4), and moderate-intensity warfarin (INR = 1.5 – 3.0). They observed that the markers of hypercoagulability TAT (thrombin-anti-thrombin complexes), D-dimers, and F1+2 decreased with the increase in oral anticoagulant intensity. However, patients with increased F1+2 levels were observed in the groups treated with placebo in the groups treated with warfarin after 3 months of treatment.

The majority of patients had an adequate intensity of anticoagulation, as we can see in table VI. Table IV summarizes INR and F1+2 levels from patients with mechanical heart valves. Considering the results presented in these tables, it can be suggested that F1+2 determination is an important tool in selecting patients at risk of developing thrombotic events, considering that the great majority of patients seemed stably anticoagulated, considering INR values as parameters. Data analysis of each patient shows that activation of the coagulation mechanism may occur, which can be verified by increased F1+2 levels, is quite adequate values for INR. This stresses the potentiality of the use of F1+2, a marker of thrombin generation, therefore, a marker of hypercoagulability, in such patients, since they have greater thromboembolic risk for eventual coagulation hyperactivation.

In the present study, 5 patients had F1+2 values above the reference range, while 14 patients were within this range and 8 patients were below it (tab. III). F1+2 increase observed in 5 patients may be explained because of heterogeneity in warfarin bioavailability, prostheses characteristics, and because of concomitant diseases 11. However, the relevance of F1+2 values observed in this study needs to be confirmed in a longer follow-up, seeking the establishment of the relationship between increased F1+2 levels and recurrence of thromboembolic events.

We must consider that our patients were undergoing oral anticoagulation therapy throughout the period of the study, and they were at potential risk of hypercoagulability resulting mainly from mechanical heart valve prostheses or, to a lesser degree in, from biological heart valve prostheses.

INR values of 2.0-3.0, corresponding to prothrombin levels of approximately 20-40% of the normal have been considered acceptable 12. However, the minimal level of each Vitamin K-dependent protein required to protect the patient from thrombosis has still not been determined. Thus, F1+2 measurement may be useful as a tool in monitoring patients receiving oral anticoagulants.

Our data questions the protective effect of warfarin against thromboembolic events once F1+2 levels are increased in some patients taking oral anticoagulants with heart valve prostheses. According to the literature, levels of hypercoagulability markers are reduced in patients receiving oral anticoagulants 4, 10. However, the use of these markers as a tool to preview thromboembolic complications has still not been well analyzed in patients with heart valve prostheses receiving oral anticoagulants or acetylsalicylic acid. Additionally, data in the literature suggest that the intensity of oral anticoagulants is associated with the level of hypercoagulability suppression. However, evidence exists of increased fibrinolytic activity as well as platelet activation, and abnormal endothelial function in patients with heart failure 12, 13. It is possible that the hypercoagulability state predisposes heart failure patients to intravascular thrombi and an increase in clinical events 10. The oral anticoagulant dosage necessary to minimize this state of hypercoagulability varies from patient to patient. Thus, reduced dosages may be efficient for some patients, but other patients may need an increased dosage of oral anticoagulants or even the combination of an oral anticoagulant and acetylsalicylic acid 14.

Comparing our data with that in the literature, F1+2 levels observed in some patients in our study were more elevated than expected taking into account that these patients were taking an oral anticoagulant. This fact stresses the importance of F1+2 use to identify patients at risk of developing thromboembolic events, even when the patient has an INR within the therapeutic range. These patients should be followed-up with greater care to find the possible causes that could justify the presence of a hypercoagulability condition. As already mentioned, several triggering factors of this condition may be interacting parallel to the thrombogenic effect of the prostheses in itself. A critical assessment of the risks of patients could result in adequate
treatment of concomitant diseases. In the absence and/or impossibility of its diagnosis, the possibility of adding an antiaggregating platelet agent to oral anticoagulant therapy must be considered. This procedure instead of increasing the need for oral anticoagulant dosing would possibly result in a reduction in the risk of thromboembolic complications (which could be verified by a new assessment of F1+2 levels) and would not increase hemorrhagic risk. This measure, probably, would result in greater efficacy and safety for the use of oral anticoagulants, providing a better quality of life for patients. However, further studies involving new experiments and others markers of coagulability in addition to F1+2 are necessary, using a larger sample of patients with heart valve prostheses to confirm whether the reduction in thromboembolic events is related to lower events of F1+2 during concomitant use of oral anticoagulants and acetylsalicylic acid.

Acknowledgments

To Fundação de Amparo à Pesquisa de Minas Gerais (FAPEMIG) (Foundation to Support Research), to CNPq, and Pró-Reitoria de Pesquisa (PRPq) of Universidade Federal de Minas Gerais by the financial support.

References